ASCO Releases Guideline for Managing Immune-Related Adverse Events of CAR-T Therapy
The guideline focuses on the treatment of CRS and ICANS in patients undergoing CAR-T therapy for hematologic cancers.
All articles by Jessica Nye, PhD
Antioxidant Vitamin Supplement Use in Breast Cancer Not Supported by Recent Studies
Researchers sought to determine whether dietary supplementation use improved survival or was a detriment for patients with newly diagnosed breast cancer.
Older, More Frail Patients With Cancer More Likely to Request Spiritual Care
Researchers sought to understand which patients are more likely to seek spiritual consultations.
Physical Manipulation Pulmonary Rehabilitation Improved Lung Function After Lobectomy for NSCLC
A randomized, controlled trial was conducted to determine if physical pulmonary rehabilitation could improve outcomes after lobectomy for patients with NSCLC.
Cardiac Events Seen in One-Fifth of AML Patients on Venetoclax Plus HMAs
Most events occurred during treatment cycles 1 and 2.
Treatment Duration and Interval of Bortezomib, Lenalidomide for MM Predictive of Skin Rash
A retrospective review sought to better understand the relationship between bortezomib and lenalidomide therapy and treatment-induced skin rash in multiple myeloma.
Radiotherapy Not Likely to Increase Toxic Effect of Immune Checkpoint Inhibitors
Researchers assessed the relationship between concomitant radiotherapy and ICI therapy and the need for corticosteroids in patients with lung cancer or melanoma.
Ankle-Brachial Index, Cardiac Ankle Vascular Index May Indicate Risk of Cardiovascular AEs in Patients With CML Taking TKIs
A retrospective analysis of data identified predictors of cardiac adverse events in patients with CML undergoing treatment with tyrosine kinase inhibitors.
PRE Training Improved Self-Efficacy, Promoted Symptom Management in Patients With Lung Cancer
Undergoing progressive relaxation exercise training improved management of distress, physical symptoms, and psychological symptoms in patients receiving chemotherapy for lung cancer.
Analysis Ranks Cost Effectiveness of First-Line Therapy Options for Advanced RCC
A model identified the most cost-effective of 6 immune checkpoint inhibitor strategies for the first-line treatment of advanced renal cell carcinoma.
- Loading...
Loading...
Next post in Renal Cell Carcinoma
Loading... 
Loading...